Neurogene, Inc. Common Stock (NGNE) is a publicly traded Healthcare sector company. As of October 5, 2026, NGNE trades at $26.46 with a market cap of $513.29M and a P/E ratio of -6.04. NGNE moved +3.31% today. Year to date, NGNE is +28.50%; over the trailing twelve months it is +18.49%. Its 52-week range spans $6.88 to $43.66. Analyst consensus is strong buy with an average price target of $84.20. Rallies surfaces NGNE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Neurogene grants inducement stock options for 8,340 shares to five new employees: Neurogene granted five new employees non-qualified stock options covering 8,340 common shares, dated Oct. 5, 2026. The options have an exercise price equal to the stock’s closing price that day and vest over four years, subject to continued employment.
| Metric | Value |
|---|---|
| Price | $26.46 |
| Market Cap | $513.29M |
| P/E Ratio | -6.04 |
| EPS | $-4.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.66 |
| 52-Week Low | $6.88 |
| Volume | 184.40K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-90.35M |
| Gross Margin | 0.00% |
7 analysts cover NGNE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $84.20.